Burleson & Co’s Erasca ERAS Stock Holding History

Burleson & Co’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-600	Closed	-$5K	–	457
2022 Q1	$5K	Hold	600	–	–	﹤0.01%	303
2021 Q4	$9K	Hold	600	–	–	﹤0.01%	270
2021 Q3	$13K	Buy	+600	New	+$12.4K	﹤0.01%	250

Other funds holding ERAS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AEPBI

AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Burleson & Co's ERAS Position: Q2 2022 in Review

Burleson & Co sold out of Erasca (ERAS) in Q2 2022, closing a stake of 600 shares — an estimated $5K sold.

Burleson & Co first reported a position in ERAS in Q3 2021 and held it in 3 quarters. The position peaked at $13K in Q3 2021. 89 funds tracked by Wall St. Rank hold ERAS as of Q2 2022.

Burleson & Co reported no remaining Erasca position as of Q2 2022 after selling out during the quarter.
Burleson & Co sold 600 Erasca shares in Q2 2022, an estimated $5K.
Burleson & Co first reported a position in Erasca in Q3 2021 and held it in 3 quarters.
Burleson & Co's Erasca position peaked at $13K in Q3 2021.
89 funds tracked by Wall St. Rank held Erasca as of Q2 2022.

Based on Burleson & Co's 13F filing for Q2 2022, filed 13 Jul 2022.